Implementation of the HIF activator IOX-2 in routine doping controls – Pilot study data

Christian Görgens | Sven Guddat | Christina Bosse | Andre Knoop | Hans Geyer | Mario Thevis

Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Cologne, Germany
European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn, Germany

Correspondence
Christian Görgens, Center for Preventive Doping Research/Institute of Biochemistry, German Sport University Cologne, Am Sportpark Müngersdorf 6, 50933, Cologne, Germany. Email: c.goergens@biochem.dshs-koeln.de

Funding information
Manfred-Donike Institute for Doping Analysis; Federal Ministry of the Interior, Building and Community of the Federal Republic of Germany; National Anti-Doping Agency

Abstract
Early in 2020, racehorse doping cases revolved around the hypoxia-inducible factor (HIF) activator IOX-2. While the composition of IOX-2 has also been known and monitored in human doping controls for several years, the testing capability of routine sports drug testing methods was revisited for this newly surfaced doping agent. IOX-2 and the analytically well-established HIF activator roxadustat (FG-4592) share identical precursor/product ion pairs, enabling their co-detection in existing initial testing procedures in routine doping controls for the intact unconjugated analytes. In addition, hydroxylated IOX-2 and the corresponding glucuronic acid conjugates were identified as major metabolites in a microdose elimination study, contributing to enhanced initial testing and confirmation procedures.

KEYWORDS
HIF activator, human urine, IOX-2, roxadustat, sports drug testing

1 | INTRODUCTION

Hypoxia-inducible factor (HIF) activators are prohibited in sports both in- and out-of-competition.1 A variety of drug candidates has been closely monitored in sports drug testing since 2012,2 and whilst clinical approval was completed in 2019 so far only for one substance (roxadustat (FG-4592), Figure 1A), various adverse analytical findings (AAFs) have been reported since 2015 for different HIF activators. One of the patented drug candidates referred to as IOX-2 was identified in the context of preventive doping research in 2012 and detected early in 2020 in a racehorse doping control sample3 (Figure 1B), and the testing capability of human routine sports drug testing methods was revisited for this newly surfaced doping agent. By association (and elemental composition), the co-detection of IOX-2 and roxadustat as intact and unconjugated analyte using identical precursor/product ion pairs was utilized (Figures 2 and 3) and since 2015, no adverse analytical findings have been recorded.4 However, to date no metabolic biotransformation reactions have been assessed.

The aim of this pilot study was the implementation of IOX-2 into an existing initial test method to enable detection at the lowest possible additional workload for the laboratory. Furthermore, a microdose elimination study was performed to identify the compound’s major metabolites and to allow a first estimation of urinary excretion profiles and detection times.

2 | EXPERIMENTAL

2.1 | Reference material and internal standard (ISTD)

IOX-2 and roxadustat reference materials were obtained from Sigma Aldrich (Deisendorf, Germany). As internal standards (ISTDs), isoxsuprine-D5 (ISTD of initial testing procedure (ITP)) and SB73 (1-chloro-7-hydroxy-6-isopropoxy-isochinoline-3-yl-glycineamide-D2, ISTD of confirmation procedure (CP), Figure 1C), both obtained from in-house syntheses were used.
2.2 | Sample preparation and instrumentation

Analytical parameters of IOX-2 using established routine doping control methods were determined from reference substance analyses. Urine sample analysis was conducted by means of fortifying an aliquot of 95 μL of urine with 5 μL of an internal standard working solution, and 10 μL was subsequently injected into the liquid chromatographic-mass spectrometric instrument.

For chromatographic separation, a Vanquish UHPLC System (Thermo Scientific, Bremen, Germany) equipped with a Nucleodur C18 Pyramide analytical column (2 x 50 mm, 1.8 μm particle size; Macherey-Nagel, Düren, Germany) and a guard column (2 x 4 mm) of the same material was used. The mobile phases were composed of A: 0.1% formic acid and B: acetonitrile. The LC gradient (total run time: 11 min) was set as follows: starting conditions 100% A, 1–5 min: 100–60% A, 5–8 min 60–10% A, 8–11 min 100% A (re-equilibration). The analytical flow rate was 200 μL/min and for re-equilibration, a flow of 350 μL/min was employed. The column temperature was set at 30°C.

Mass spectrometric experiments were carried out using an Exploris 480 orbitrap mass spectrometer (Thermo Scientific, Bremen, Germany) operating in full scan (scan range: m/z 100–800; orbitrap resolution: 60,000 FWHM) and data independent
acquisition (DIA) (Q1 isolation window: m/z 100; stepped normalized collision energy (NCE): 30 and 55%; orbitrap resolution: 60000 FWHM) mode for initial testing procedure (ITP). In the case of a confirmatory analysis, identical chromatographic conditions were chosen, but with parallel reaction monitoring (PRM) mode (Q1 resolution: m/z 1.0; NCE: 30%; orbitrap resolution: 60000 FWHM) for the mass spectrometric detection and unambiguous identification of the compound.

2.3 | Microdose elimination study

With written consent, a microdose elimination study was performed with one healthy male volunteer (64 years, 81 kg, 170 cm), who was orally administered 1 mg of IOX-2. Urine samples were collected before and up to 91 h post-administration, and specimens were subjected to routine doping control analytical approaches (dilute-and-inject) as well as dedicated product ion scan experiments on in silico predicted phase I and phase II metabolites.

2.4 | Method validation

The method for the semi-quantitative determination of IOX-2 was comprehensively characterized with regard to the following parameters according to World Anti-Doping Agency (WADA) guidelines: Selectivity: Ten different blank urine samples obtained from healthy volunteers were tested for the presence of interfering
signals using the initial testing procedure (ITP) as well as the confirmation procedure (CP).

**Carryover:** The carryover was assessed by analyzing one sample with a concentration set at 400% of the MRPL (8.0 ng/mL) followed by the injection of one blank sample.

**Limit of detection (LOD):** The LOD is the lowest concentration of an analyte that can be detected in 95% of representative samples (ie 95% detection rate). Here, in each case six urine samples were fortified with 0.02–2.00 ng/mL of IOX-2 and analyzed using the ITP.

**Robustness:** The robustness of the approach was determined by analyzing six different urine specimens spiked at 50% of the minimum required performance level (MRPL) of the compound (1.0 ng/mL). The coefficients of variation (%CV) were calculated on the basis of the ISTD-normalized peak areas as well as relative retention times (rRT). Robustness was estimated using the CP.

**Limit of identification (LOI):** The LOI is the lowest concentration of an analyte that meets the WADA Technical document TD IDCR criteria in 95% of representative samples (ie 95% identification rate or 5% false-negative rate). Here, in each case six urine samples were fortified with 0.02–2.00 ng/mL of IOX-2 and analyzed using the CP.

**Linearity:** Calibration curves in the range 0.25–125 ng/mL (0.25, 1.0, 25, 50, 75, 100, 125 ng/mL) were constructed using the ISTD-normalized peak areas and linearity was determined by regression analysis.

### RESULTS

#### 3.1 Implementation of IOX-2 into routine doping control

Roxadustat (Figure 1A) and IOX-2 (Figure 1B) exhibit the identical sum formulae of C_{19}H_{16}N_{2}O_{5}, and the fact that the structurally related pharmacophores both comprise a glycineamide side chain suggested similar collision-induced dissociation behaviors as reported in 2017 and corroborated in Figure 2. The monitoring of diagnostic product ions such as m/z 307, 296, and 278 enabled the detection of intact IOX-2 alongside intact roxadustat in LC-FullMS-DIA-HRMS routine analyses, with both analytes separated in retention time by approximately 0.5 min (Figure 3). In addition to the unmodified intact substance of IOX-2, its hydroxylated analog and the corresponding glucuronic acid conjugates were also detected in post-administration urine samples (Figure 3), supporting both initial testing and confirmation procedures in routine doping controls.

#### 3.2 IOX-2 excretion profile and detection window

As demonstrated in Figure 4, the urinary excretion profiles of the intact drug, as well as the identified major metabolites follow a similar excretion profile with peak concentrations between 4 and 6 hours after application of the substance. All metabolites including the unmodified intact compound were detectable up to 91 h following ingestion of 1 mg of the substance. The maximum concentration of IOX-2 was found to be approximately 140 ng/mL in a urine sample collected 4 h after administration. The last urine sample collected 91 h post administration provided an IOX-2 concentration of approximately 0.4 ng/mL, while hydroxylated IOX-2 and the corresponding phase II metabolites were also detectable.

In a phase 3 clinical trial for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naïve chronic kidney disease patients on dialysis, patients were treated with 50–70 mg of roxadustat 3 times weekly. Consequently, the effective doses in clinical trials of related HIF activators are substantially higher than the performed microdose elimination study. Therefore, a significant extension of the detection window in a potential doping scenario seems possible.

#### 3.3 Retrospective monitoring of urinary IOX-2 metabolites

Due to the fact that routine doping controls of roxadustat and IOX-2 have been performed using LC-FullMS-DIA-HRMS, retrospective evaluation of IOX-2 metabolites was possible. Despite the co-detection of IOX-2 and roxadustat in routine doping control samples, another 2000 randomly chosen routine doping control samples were evaluated using LC-FullMS-DIA-HRMS.
samples from in- and out-of-competition as well as of different sports and gender were retrospectively evaluated for the presence of hydroxylated IOX-2, IOX-2 glucuronide, and hydroxylated IOX-2 glucuronide. In none of the cases examined, were IOX-2 or any of the described metabolites found.

3.4 | Method validation

The method employed for a semi-quantitative determination of IOX-2 after direct injection of native urine specimens treated with ISTD was comprehensively characterized in accordance with WADA criteria. The results of the method validation are summarized in Table 1. According to the fact that the aforementioned IOX-2 metabolites are not commercially available, most of the described method validation parameters (robustness, LOD, LOI, and linearity) were estimated with IOX-2 itself, while selectivity and carryover was done for all the investigated metabolites. The assay is characterized by a high selectivity with almost zero biological noise in the blank urine specimens for IOX-2 and all investigated IOX-2 metabolites. The approach was found to be linear from 0.25 to 125 ng/mL (R² > 0.9971) with an LOD (ITP) of 0.6 ng/mL and an LOI (CP) of 0.4 ng/mL. Furthermore, the assay demonstrates adequate robustness (CV% rRT: 0.1; CV% area ratio: 13.3) and carryover (< 1%).

4 | CONCLUSIONS

IOX-2 can adequately be covered in routine doping controls by targeting the intact drug and its hydroxylated metabolite, and the capability of the combined detection of IOX-2 and roxadustat was demonstrated. The performed pilot microdose elimination study indicates a similar excretion profile of the intact IOX-2 and the identified major urinary metabolites with detection windows longer than 91 h post oral administration of 1 mg of the substance. Although the compound has a high (mis)use potential in sports, retrospective monitoring for IOX-2 and its metabolites indicates that the drug is not likely to have been widely abused over the time period of assessment. However, further studies are indicated in order to complement the pattern of urinary metabolites and their utility in terms of enhanced retrospective.

ACKNOWLEDGMENTS

The presented work was conducted with support of the National Anti-Doping Agency (NADA, Bonn, Germany), the Federal Ministry of the Interior, Building and Community of the Federal Republic of Germany, and the Manfred-Donike Institute for Doping Analysis (Cologne, Germany). Open access funding enabled and organized by Projekt DEAL.

ORCID

Christian Görgens  https://orcid.org/0000-0001-6061-0407
Andre Knoop  https://orcid.org/0000-0003-0040-8754
Mario Thevis  https://orcid.org/0000-0002-1535-6451

REFERENCES

1. World Anti-Doping Agency. The world anti-doping code – international standard: prohibited list 2020. Available at: https://www.wada-ama.org/sites/default/files/wada_2020_english_prohibited_list_0.pdf Accessed: 10 July 2020
2. Beuck S, Schänzer W, Thevis M. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test Anal. 2012;4(11):830-845.
3. Synthetic doping agent detected in two Standardbreds. Available at: https://www.thoroughbreddailynews.com/synthetic-doping-agent-detected-in-two-standardbreds (Accessed: 23 January 2020)

4. Buisson C, Marchand A, Bailloux I, Lahaussois A, Martin L, Molina A. Detection by LC-MS/MS of HIF stabilizer FG-4592 used as a new doping agent: investigation on a positive case. J Pharm Biomed Anal. 2016;121:181-187.

5. Görgens C, Guddat S, Thomas A, et al. Simplifying and expanding analytical capabilities for various classes of doping agents by means of direct urine injection high performance liquid chromatography high resolution/high accuracy mass spectrometry. J Pharm Biomed Anal. 2016;131:482-496.

6. World Anti-Doping Agency. International standard for laboratories (ISL 10.0). Available at: https://www.wada-ama.org/sites/default/files/resources/files/isl_nov2019.pdf (Accessed: 10 August 2020)

7. World Anti-Doping Agency. Technical document on the minimum criteria for chromatographic-mass spectrometric confirmation of the identity of analytes for doping control purposes (TD IDCR). Available at: https://www.wada-ama.org/sites/default/files/resources/files/td2015idcr_-_eng.pdf (Accessed: 10 July 2020)

8. Eichner D, Van Wagoner RM, Brenner M, et al. Implementation of the prolyl hydroxylase inhibitor Roxadustat (FG-4592) and its main metabolites into routine doping controls. Drug Test Anal. 2017;9:1768-1778.

9. Akizawa T, Yamaguchi Y, Otsuka T, Reusch M. A phase 3, multicenter, randomized, two-arm, open-label study of intermittent oral dosing of Roxadustat for the treatment of anemia in Japanese erythropoiesis-stimulating agent-naive chronic kidney disease patients not on dialysis. Nephron. 2020;144(8):372-382.

How to cite this article: Görgens C, Guddat S, Bosse C, Knoop A, Geyer H, Thevis M. Implementation of the HIF activator IOX-2 in routine doping controls - Pilot study data. Drug Test Anal. 2020;12:1614–1619. https://doi.org/10.1002/dta.2914